Boston Scientific boosts buyback by $4B to $5B; appoints two new directors

BOSTON SCIENTIFIC CORP

Board approved additional $4.0B stock repurchase authorization, total available now $5.0B.
Board expanded from 10 to 12; appointed Catherine R. Smith (CFO of Starbucks) and Christophe P. Weber (CEO of Takeda).
Smith and Weber will serve on audit and compensation committees; standard prorated compensation until 2026 annual meeting.
Former directors John Sununu and Yoshiaki Fujimori will not stand for re-election at 2026 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.